MapleStory Fest at Home 2020 Unites Maplers Around the World with All-Digital Event
16.11.2020 17:00:00 EET | Business Wire | Press release
Maplers around the world gathered to celebrate their favorite games: MapleStory and MapleStory M . Garnering over 20,000 views, MapleStory Fest 2020 at Home brought fans together for the virtual festivities. Fans enjoyed special announcements, greetings from developers, live engagement events, including quizzes, a fan art contest, and several giveaways.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005446/en/
MapleStory Fest at Home 2020 Banner (Graphic: Business Wire)
The event kicked off with a teaser of MapleStory M’s highly anticipated new Demon Avenger class available in-game starting on December 1. MapleStory M developers also answered community questions based on feedback gathered through various platforms announcing several improvements.
Maplers were also treated to the latest news surrounding MapleStory with the announcement of the Awake two-part content update. The first installment, Awake: Ascend to Mastery, will be landing on November 18 featuring new 5th Job skills for all classes, Grand Athenaeum Episode 6: Sharenian Knights and character level-up events, including the return of Burning World.
The second part of the update, Awake: Flicker of Light, will include Reboot world improvements with the addition of Zero character creation, new areas, seasonal events, and exclusive Global MapleStory content slated to hit on December 16.
After receiving hundreds of submissions, viewers came together to vote for the most creative fan art and MapleStory and MapleStory M guild group screenshots. During the event, a special community video was shown featuring MapleStory and MapleStory M players sharing their favorite Maple world memories.
Winners of the MapleStory Fest 2020 in-game prizes were also announced throughout the event from over 6,000 entries received. Nexon also partnered with HyperX to create an exclusive MapleStory Fest 2020 Cloud Alpha headset raffled during a social media promotion. Hyper X also provided various free products raffled throughout the event.
On November 12, Nexon Korea's CEO, Jung-Hun Lee, announced a collaboration event between popular anime series, Attack on Titan , and its mobile MMORPG, MapleStory M . A key figure from Attack on Titan will offer special quests until November 25. Based on the manga "Shingeki no Kyojin" by Hajime Isayama originally serialized in the Monthly BESSATSU SHONEN magazine published by Kodansha Ltd. ©Hajime Isayama,Kodansha/"ATTACK ON TITAN"Production Committee. All Rights Reserved.
To learn more about the content updates announced at the event, please visit the MapleStory Fest 2020 at Home website and follow @MapleStory and @PlayMapleM on Twitter for the latest news.
Assets:
- MapleStory Fest 2020 Assets
- MapleStory Fest 2020 at Home Highlights Video
- MapleStory Awake Update Preview
- MapleStory M Demon Avenger Trailer
- MapleStory M Attack on Titan Assets
Social Media:
- MapleStory: Twitch / Facebook / Twitter / YouTube / Website
- MapleStory M: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 15 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the epic franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 2-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116005446/en/
Contact information
Nexon America
Cynthia Lezama
clezama@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom